Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of this study are to determine the safety of oral enzastaurin and any side effects that might be associated with it and whether enzastaurin can help participants with mantle cell lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Mantle cell lymphoma

• Previous treatment for mantle cell lymphoma

• Previously relapsed mantle cell lymphoma with no more than 4 chemotherapy regimens.

• Have discontinued all previous therapies for cancer, except corticosteroids up to 25 milligrams per day (mg/day)

• Adequate organ function

Exclusion Criteria:

• Inability to swallow tablets

• Must not have significant heart problems